Gilead Sciences: Is There Upside in Hepatitis C?

Gilead Sciences (GILD) has been hit hard this year thanks to concerns surrounding its hepatitis-C treatments. Citigroup’s Robyn Karnauskas and Mohit Bansal argue that Gilead’s hep-C sales could be higher than expected. They explain why:

Read more.

Related

JOIN THE DISCUSSION